In an affidavit filed in the Supreme Court, Uttarakhand licencing authority said that it had suspended licenses of 14 products manufactured by Patanjali’s Divya Pharmacy.
Patanjali is under scrutiny in Uttarakhand as licences for 14 of its products have been Cancelled.
On Monday, the Uttarakhand licensing authority suspended the licenses of 14 Patanjali products with immediate effect.
In an affidavit filed in Supreme Court, the licensing body stated that it had suspended the licenses of 14 products produced by Patanjali’s Divya Pharmacy in relation to the misleading advertisements case.
“The SLA issued an order, dated April 15, 2024, to Divya Pharmacy and Respondent No. 5-Patanjali Ayurved Ltd., stating therein that the manufacturing licenses for 14 of their products, namely ‘Swasari Gold’, ‘Swasari Vati, Bronchom’, ‘Swasari Pravahi’, ‘Swasari Avaleh’, ‘MuktaVati Extra Power’, ‘Lipidom’, ‘Bp Grit’, ‘Madhugrit’, ‘MadhunashiniVati Extra Power’, ‘Livamrit Advance’, ‘Livogrit’, ‘Eyegrit Gold’ and ‘Patanjali Drishti Eye Drop’, are suspended with immediate effect under Rule 159(1) of The Drugs and Cosmetics Rules, 1945,” it said.
The District Ayurvedic and Unani Officer in Haridwar lodged a criminal complaint with the Chief Judicial Magistrate against Swami Ramdev, Acharya Balkrishna, Divya Pharmacy, and Patanjali Ayurved Limited. The complaint is filed under Sections 3, 4, and 7 of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954,” as stated in the affidavit.
The State Licensing Authority (SLA) declared its intent to pursue all necessary and subsequent actions against Divya Pharmacy and Patanjali Ayurved Ltd in accordance with the procedures outlined in the law and the directives issued by the Supreme Court.
In an order issued on April 10, the Supreme Court directed the then Joint Director of the State Licensing Authority and all officers serving as District Ayurvedic and Unani Officers in Haridwar from 2018 to the present to submit their individual affidavits elucidating their lack of action in the matter.
The Indian Medical Association has requested action against Patanjali for breaching the Drugs and Magic Remedies (Objectionable Advertisements) Act, which prohibits the promotion of specific products for the treatment of designated diseases and conditions such as diabetes, heart diseases, high or low blood pressure, and obesity.
Also Read: AstraZeneca admits its Covishield vaccine may lead to rare side effect
The ayurvedic company had previously given an assurance to the Supreme Court, stating that it would refrain from making any unfounded statements regarding the medicinal effectiveness of its products, nor would it advertise or brand them in contravention of the law. Additionally, the company committed not to issue any statements against any system of medicine through the media in any format.
In Short
- Uttarakhand authority suspends licences of 14 Patanjali products
- Suspension linked to misleading advertisements case
- Products include Drishti Eye drop, Madhugrit and Swasari Gold
The Uttarakhand State Licensing Authority has suspended the license of 14 Patanjali products with immediate effect for not complying to notice issued in the misleading advertisement case. pic.twitter.com/LOksVSApqb
— Piyush Rai (@Benarasiyaa) April 29, 2024